Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 651-658

  Beyer Westendorf, Jan ^a   Michalski, Franziska ^a   Tittl, Luise ^a   Middeldorp, Saskia ^b   Cohen, Hannah ^c   Abdul Kadir, Rezan ^d   Arachchillage, Deepa Jayakody ^e   Arya, Roopen ^f   Ay, Cihan ^g   Marten, Sandra ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Direct oral anticoagulants; Outcome; Pregnancy

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMBRYOPATHY; EMBRYOTOXICITY; FACE DYSMORPHIA; FALLOT TETRALOGY; HEART DISEASE; HIP DYSPLASIA; HUMAN; HYDRAMNIOS; LIMB DISEASE; LIVE BIRTH; PATIENT COUNSELING; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRIORITY JOURNAL; PUBLICATION; SCIENTIFIC LITERATURE; SEPTUM PELLUCIDUM CYST; SPONTANEOUS ABORTION; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; FEMALE; PREGNANCY;

ABORTION, SPONTANEOUS; ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; HUMANS; LIVE BIRTH; PREGNANCY; PREGNANCY OUTCOME;

EID: 84989200149     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-04-0305     Document Type: Article

References (41)

1. Astedt B. Thrombotic and hemostatic problems in pregnancy and labor and their significance for the fetus and newborn infant. Padiatr Padol 1990; 25: 43–53.
2. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol 1997; 11: 479–488.
3. Walfisch A, Koren G. The „warfarin window“ in pregnancy: the importance of half-life. J Obstet Gynaecol Can 2010; 32: 988–989.
4. Pauli RM, Hall JG. Warfarin embryopathy. Lancet 1979; 2: 144.
5. Sathienkijkanchai A, Wasant P. Fetal warfarin syndrome. J Med Assoc Thai 2005; 88 (Suppl 8): S246–250.
6. Kumar M, Bhasker SK, Singh R, et al. Di Sala syndrome. Br Med J Case Rep 2012; 2012.
7. Mehndiratta S, Suneja A, Gupta B, et al. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet 2010; 282: 335–357.
8. Hetzel PG, Glanzmann R, Hasler PW, et al. Coumarin embryopathy in an extremely low birth weight infant associated with neonatal hepatitis and ocular malformations. Eur J Pediatr 2006; 165: 358–360.
9. van Driel D, Wesseling J, Sauer PJ, et al. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology 2002; 66: 127–140.
10. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390–1393.
11. Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95: 949–957.
12. Baglin T, Bauer K, Douketis J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 2012; 10: 698–702.
13. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968–1975.
14. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
15. Bapat P, Kedar R, Lubetsky A, et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 2014; 123: 1256–1261.
16. Bapat P, Pinto LS, Lubetsky A, et al. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015; 213: 710e1–6.
17. SmPC rivaroxaban, July. Available at: http://www.medicines.org.uk/emc/medicine/25586/SPC. Accessed January 6, 2016.
18. SmPC apixaban, October. Available at: http://www.medicines.org.uk/emc/medicine/24988. Accessed January 6, 2016.
19. SmPC dabigatran, September. Available at:http://www.medicines.org.uk/EMC/medicine/24839/SPC/Pradaxa+150. Accessed January 6, 2016.
20. SmPC edoxaban, July. Available at: http://www.medicines.org.uk/emc/medi cine/30512. Accessed January 6, 2016.
21. Konigsbrugge O, Langer M, Hayde M, et al. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost 2014; 112: 1323–1324.
22. Hoeltzenbein M, Beck E, Meixner K, et al. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol 2015; Epub ahead of print.
23. US Food and Drug Administration, Center for Drug Evaluation and Research, 202155Orig1s000, Apixaban Clinical Review Addendum. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155orig1s000medr.pdf. Accessed January 6, 2016.
24. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453–1472.
25. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80: 337–345.
26. Vaillant-Roussel H, Ouchchane L, Dauphin C, et al. Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives. Contraception 2011; 84: e23–30.
27. WHO. Medical Eligibility Criteria for Contraceptive Use, World Health Organization; 2010.
28. Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2015; Epub ahead of print.
29. Cohen H, Arachchillage D, Middeldorp S, et al. Management of Direct Oral Anticoagulants in Women of Childbearing Potential: Guidance from the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2016; Epub ahead of print.
30. Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457.e1–21.
31. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-736S.
32. Savitz DA, Hertz-Picciotto I, Poole C, et al. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev 2002; 24: 91–101.
33. Garcia-Enguidanos A, Calle ME, Valero J, et al. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol 2002; 102: 111–119.
34. Buss L, Tolstrup J, Munk C, et al. Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta Obstet Gynecol Scand 2006; 85: 467–475.
35. Hothi DK, Wade AS, Gilbert R, et al. Mild fetal renal pelvis dilatation: much ado about nothing? Clin J Am Soc Nephrol 2009; 4: 168–177.
36. Sewell MD, Rosendahl K, Eastwood DM. Developmental dysplasia of the hip. Br Med J 2009; 339: b4454.
37. Irvine B, Luo W, Leon JA. Congenital anomalies in Canada 2013: a perinatal health surveillance report by the Public Health Agency of Canada’s Canadian Perinatal Surveillance System. Health Promot Chronic Dis Prev Can 2015; 35: 21–22.
38. SSC: Women’s Health Issues in T&H. Available at: http://www.isth.org/members/group.aspx?id=100375. Accessed February 9, 2016.
39. Wang L, He K, Maxwell B, et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 2011; 39: 256–264.
40. Boehringer Ingelheim. Advisory committee briefing document on dabigatran etexilate. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf. Accessed May 24, 2016.
41. Lock, IBD, Bayer HealthCare. INVESTIGATOR’S BROCHURE. Available at: http://quovadis-ass.it/resources/Altre/Rivaroxaban_Investigator-Brochure_BAY-59–7939_V21.0.pdf. Accessed May 24, 2016.